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Abstract
The much-publicised halting of the joint Merck/HIV Vaccine Trials Network phase IIB candidate
HIV-1 vaccine trial in 2007 has led to an unprecedented degree of discussion and introspection
amongst the HIV research community. In this commentary, we will summarise the lessons learned
from the trial and examine the current state of HIV vaccine research.
Introduction and context
The Merck/HIV Vaccine Trials Network (HVTN) 502
study, called STEP, started in late 2004 and was
terminated in September 2007. The phase IIB test-of-
concept, double-blinded, placebo-controlled trial was
conducted in North and South America, the Caribbean,
and Australia (areas where the predominant HIV-1
subtype is clade B). The aim of the STEP trial was to
generate a potent HIV-specific T-cell response, with the
hope of either conferring protection against infection or
decreasing ‘set-point’ plasma viraemia in subjects who
subsequently became infected with HIV-1, thus reducing
disease progression and potential viral transmission.
Almost 3,000 healthy uninfected young adult volunteers
considered to be at high risk of HIV-1 infection were
involved. Vaccinated subjects received three immunisa-
tions of three replication-defective adenoviral vectors
(rAd5), each carrying a gene encoding an HIV clade B
protein (Gag, Pol and Nef). At the time the trial was
started, this vaccine was the leading T-cell candidate and
had elicited the highest levels of T cell responses in phase
I studies [1]. As specified in the protocol, the trial data
were reviewed by the Data and Safety Monitoring Board
after 30 subjects had become infected. The trial was then
terminated because there was no apparent vaccine
efficacy, and - worryingly - a trend was noted for an
increased risk of infection in vaccinated subjects with
high titres of pre-existing neutralising antibodies (nAbs)
against adenovirus serotype 5 (Ad5), from which the
vector was derived [2,3]. Inevitably, halting the trial at
this stage meant that subsequent analysis was limited by
small numbers, a total of 49 infections in the vaccinated
group and 33 in the placebo group.
Overall, the STEP vaccine was as immunogenic as had
been predicted from earlier human studies, eliciting
significant interferon-gamma (IFN-g secretion in
response to two or three of the HIV proteins in most
subjects, detected by enzyme-linked immunosorbent
spot (ELISpot) assay, in 77% of vaccinees [3]. Moreover,
high frequencies of polyfunctional HIV-specific CD4
+
and CD8
+ T cells were observed following vaccination,
however,thesewereprimarilyIFN-g
+ andIFN-g
+/tumour
necrosis factor-alpha-positive (TNF-a
+) cells as opposed
to interleukin-2-positive (IL-2
+), IFN-g
+, TNF-a
+ T cells,
whichareregardedasbeingfullypolyfunctional.Interms
of magnitude, breadth and functionality, the vaccine-
induced responses in those who became infected were
not significantly different from the responses in those
who remained uninfected [3]. However, despite the
encouraging early data in humans, the response to the
Ad5vectorhadbeen-withhindsight-lessencouragingin
studies conducted in non-human primates [4]. Although
there had been evidence of a reduction in viral load of
1 to 3 logs in vaccinated macaques following challenge
with SHIV [a chimaeric virus expressing HIV internal
genes and simian immunodeficiency virus (SIV) envel-
ope] [5], a more stringent challenge with the more
virulent SIV strain, SIVmac239, led to just a modest
(1 log) decrease of viral load, which was seen only in
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ity complex class I allele Mamu-A*01 [6]. It has been
argued that more attention needs to be paid to the
outcome of appropriate macaque challenge models in
selecting the vaccine candidates that go through to large
clinical trials in humans [7].
Although the numbers of new HIV-1 infections in the
STEP trial were too small to demonstrate unequivocally
that pre-existing Ad5 immunity actually increased
susceptibility to infection, there was a trend toward a
higher infection rate in subjects with high titres of Ad5-
specific nAbs, particularly in uncircumcised men, how-
ever, the data could also be interpreted - somewhat
paradoxically - as showing a lower rate of infection in
placebo recipients with high Ad5 antibody titres [8]. If
pre-existing Ad5 immunity really does increase HIV-1
susceptibility, one possible mechanism would be a
vaccine-mediated increase in immune activation leading
to a larger pool of activated HIV-susceptible T cells. In
order to address this question, cellular immune activa-
tion and expression of HIV-1 co-receptors were studied
in infected and uninfected vaccine recipients with
different levels of Ad5 antibodies. Activation levels
were in fact higher in those with higher antibody titres,
but only in placebo recipients and in vaccine recipients
who did not become infected, suggesting that cellular
activation did not play a major part in increasing
susceptibility in those with prior Ad5 immunity. Never-
theless, in vitro studies have shown that Ad5-antibody
immune complexes can promote HIV-1 infection by
inducing dendritic cell maturation and enhancing HIV-1
transmission to T cells [9]. Moreover, prior adenoviral
immunity impinged on vaccine immunogenicity: fre-
quencies of HIV-specific CD8
+ T cells were significantly
lower in subjects with pre-existing Ad5 nAbs compared
with naïve subjects [3]. However, examination of further
data from the STEP trial, looking at participants who,
despite extensive counselling, became infected after the
trial was terminated, shows that the effect of pre-existing
adenovirus immunity no longer has an impact on the
likelihood of infection in vaccines (Julie McElrath,
presentation at the Keystone meeting on HIV prevention,
March 2009).
Major recent advances
Does the setback of the STEP study imply that the general
concept of T cell-based vaccine is flawed or is this simply
a failure of a particular product? Could other T cell
vaccination regimens using different vectors fare better?
Recently, Liu and colleagues [10] succeeded in eliciting a
protective T-cell response against SIV using an immuni-
sation strategy similar to that of the STEP study, but
using two different adenovirus vectors. Significant
protection of rhesus monkeys from challenge with
SIVmac251 was afforded following immunisation with
an rAd26-Gag prime/rAd5-Gag boost regimen. This
heterologous prime-boost strategy elicited a Gag-specific
T-cell response of higher magnitude, breath and poly-
functionality than the rAd5-Gag prime/rAd5-Gag strat-
egy used in the STEP study, and this correlated with
control of set-point viral loads. HIV-specific T cells were
primarily IL-2
+ (as opposed to IFN-g
+ generated with the
rAd5-Gag prime/rAd5-Gag regimen and the STEP study),
and gastrointestinal CD4
+ T cells and peripheral CCR5
+
central memory CD4
+ T cells were preserved. These
results strongly suggest that the use of vectors other than
the Ad5 vector used during the STEP trial should be
considered and provide encouragement that a setback of
the STEP trial does not imply a failure of the overall
T cell-based vaccine concept. Following a period of
considerable introspection after the STEP trial, HIV
vaccine researchers have identified some critical con-
siderations to be addressed before embarking upon
further large-scale clinical vaccine studies.
Achieving a better fundamental understanding of the
pathogenesis and immune response to HIV-1 infection
The critical featuresof protective immunity against HIV-1
infection remain poorly understood because, in contrast
to most infections for which we have effective preventa-
tive vaccine, there are no records of any individuals
having completely eliminated the virus. Continued
studies of people with a good outcome of their
encounter with HIV-1 infection (HEPS [highly exposed
persistently seronegative] subjects and those with long-
term viral control, not only with HIV-1 but also with
HIV-2 infection [11]), as well as new and improved
animal models, are needed to determine the correlates of
protective immunity.
Improving the definition of the correlates of
T cell-mediated protection during HIV infection
and following vaccination
It has been well established that neither the magnitude
nor the breadth of the HIV-specific IFN-g response
measured by ELISpot assays correlates with any clinical
parameter in infected patients [12], strongly implying
that there are better functional correlates of an effective
antiviral T-cell response. Migueles and colleagues [13]
recently developed an assay that detects the delivery of
functional Granzyme B into HIV-infected cells. Lytic
granule loading of effectors and delivery to target cells
are critical determinants of cytotoxicity and immunolo-
gic control. Assuming that diminished killing capacity
of HIV-specific cytotoxic CD8
+ T cells is due to deficient
loading of lytic granules into targets, such an assay
should be considered in the testing of new vaccines.
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(IL-2
+, IFN-g
+, TNF-a
+) correlates with delayed disease
progression [14], the concept of polyfunctionality
should be more clearly defined: could other even more
critical soluble factors or effector functions be identified?
Furthermore, the field needs to develop assays to
measure renewal and persistence of the memory T-cell
response. Hansen and colleagues [15] have shown that
SIV-infected rhesus macaques vaccinated with a RhCMV
(rhesus cytomegalovirus) vector expressing SIV Gag,
Rev-Tat-Nef and Env developed robust and sustainable
CD4
+ and CD8
+ T-cell responses that were sufficient to
mediate protection against infection with the highly
pathogenic strain, SIVmac239, after repeated mucosal
challenges. Protection was associated with effector
memory T (TEM) cells producing TNF-a, IFN-g and
MIP-1b (macrophage inflammatory protein-1-beta) in
the absence of nAbs [15]. This implies that TEM cells may
have the ability to prevent sexual transmission of HIV,
hence correlates of functional memory need to be easily
identifiable. Progressive impairment of T cell fitness
during chronic infection is also an important parameter.
T cell exhaustion and senescence correlate with an
increase in viral load [16], whilst preservation of
proliferative capacity is associated with viral control
[17,18]. The ability of T cells to suppress virus in vitro
may be a better indication of their antiviral potency and
does not always correlate with other assays of T cell
function [19]; it would be valuable to develop similar
suppression assays that could be scaled up in vaccine
studies. Lastly, although blood remains the most
accessible tissue, recent appreciation that crucial immu-
nopathological events occur in mucosal compartments
early after infection [20,21] suggests that sampling these
sites may provide more relevant data about pathogenesis
and protective immunity. Studies of non-human pri-
mates infected with SIV would be useful in determining
whether this approach is feasible.
A better characterisation of the innate response to HIV-1
would influence the quality and magnitude of
the adaptive immune response
The strong relationship between KIR (killer immunoglo-
bulin-like receptor) genotypes and HIV-1 disease out-
come [22,23] strongly suggests that natural killer (NK)
cell responses are likely to play an important role at early
stages of infection and thus be decisive for the outcome
of disease, but correlates of an effective innate immune
response are still ill defined and it is not yet clear how
this may be influenced by vaccine strategies [24].
Selecting alternative vaccine vectors
Other vectors, such as other adenoviral vectors that rarely
cause infection in humans (for example, simian and
ovine adenoviruses), and poxviruses, merit further study.
The impact of pre-existing immunity as well as the
immune response to these vectors should be charac-
terised in detail. Poxvectors are a particularly promising
option since most individuals born after 1974 have not
been in contact with the virus, thus preventing the
scenario that appeared to be an issue during the STEP
study. It is also important to consider that similar vectors
are being developed for other novel vaccines, such as for
tuberculosis and malaria, so consideration should be
given to how these vaccines can be effectively used
together.
Determining whether a broadly neutralising antibody
response against HIV-1 infection is achievable
Given that most of the successful licensed vaccines rely
on the generation of virus-specific nAbs and that
administration of high doses of broadly neutralising
monoclonal antibodies provides sterilising immunity to
HIV [25], it has become imperative to determine how
this could be achieved in the context of HIV infection.
Masking of epitopes by glycosylation and the high
mutation rate of the viral envelope are two main reasons
why nAbs against HIV are difficult to induce [26].
However, other antibody-mediated antiviral activities
such as antibody-dependent cell-mediated cytotoxicity
in October 2003, involved more than 16,000 healthy
uninfected volunteers and will be completed by June
2009. The vaccination strategy was as follows: (a) at
weeks 0, 4, 12 and 24, subjects were primed with
ALVAC-HIV (vCP1521), a recombinant canarypox vector
expressing subtype E HIV-1 gp120 linked to a transmem-
brane anchoring portion of gp41, and HIV-1 Gag and
protease, and (b) at weeks 12 and 24, subjects were given
a bivalent AIDSVAX B/E gp120 boost [27]. Preliminary
results showed that the vaccine induced a potent ADCC
significantly different from that of placebo recipients. In
previous phase I/II testing, this regimen induced higher
binding and nAb titres and a lymphoproliferative
response in vaccine recipients compared with the
placebo group. Whether this prime-boost vaccine com-
bination can afford protection against HIV is not yet
known, but the presence of gp120 ADCC antibodies
following vaccination is encouraging.
Learning from other successful anti-viral vaccines
Inspiration for the HIV vaccine endeavour has been
sought from other vaccines that have been successful at
eliciting protective immunity [28,29]. Recently, micro-
array transcriptional profiling and multiplex cytokine
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(ADCC) may be equally valuable. The phase III trialof
Thailand is promising in this regard. This study started
gp120 B/E (AIDSVAX B/E) prime-boost vaccine in
the Aventis Pasteur ALVAC-HIV (vCP1521)/VaxGenanalysis revealed that activation of master-switch genes
following yellow fever vaccination induces several path-
ways of innate and adaptive immune response,including
complement, Th1/Th2 polarisation and B cells [30]. This
approach permitted the identification of a distinct
signature of gene activation and accurately predicted
CD8
+ T-cell and B-cell responses. Thus, new technologies
and system biology approaches should be included in
future studies in order to decipher the intricacy of HIV
and to assist the design of future effective vaccines.
Future directions
In summary, the next generation of HIV vaccines will
probably need to elicit broader and more polyfunctional,
potent, and persistent T-cell responses than those
achieved in the STEP study and then may provide partial
protection against HIV-1 infection. T cell immunity
could be enhanced by mobilising innate immunity (NK
cells in particular), whilst the generation of a broadly
nAb response remains elusive. Huge challenges never-
theless will remain to generate vaccines that can
effectively protect against the multiplicity of HIV-1
variants that have emerged worldwide in the past few
decades and to combat the ability of this virus to create
latent lifelong reservoirs.
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